BiotechTube

GTAEXS617 + SoC

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Head and Neck Squamous Cell Carcinoma (HNSCC)

Conditions

Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC), Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, Triple Negative Breast Cancer (TNBC)

Trial Timeline

Jul 6, 2023 → May 1, 2028

NCT ID
NCT05985655

About GTAEXS617 + SoC

GTAEXS617 + SoC is a phase 1/2 stage product being developed by Recursion Pharmaceuticals for Head and Neck Squamous Cell Carcinoma (HNSCC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT05985655. Target conditions include Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC).

What happened to similar drugs?

11 of 20 similar drugs in Head and Neck Squamous Cell Carcinoma (HNSCC) were approved

Approved (11) Terminated (0) Active (9)
✅Galcanezumab-GnlmEli LillyApproved
✅Ubrogepant 50 MG [Ubrelvy] + Ubrogepant 100 MG [Ubrelvy]AbbVieApproved
✅Placebo + Zolmitriptan + Zolmitriptan + ZolmitriptanAstraZenecaApproved
✅Propranolol or nadolol + Placebo control + Optimal Acute TherapyMerckApproved
✅Pembrolizumab + Carboplatin + PaclitaxelMerckApproved
✅Erenumab 70 mg + Erenumab 140 mg + PlaceboAmgenApproved
✅Rimegepant + ZavegepantPfizerApproved

Hype Score Breakdown

Clinical
9
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05985655Phase 1/2Recruiting

Competing Products

20 competing products in Head and Neck Squamous Cell Carcinoma (HNSCC)

See all competitors
ProductCompanyStageHype Score
Abametapir Lotion 0.74% w/w + Vehicle LotionDr. Reddy's LaboratoriesPhase 3
37
DFN-15 ActiveDr. Reddy's LaboratoriesPhase 3
37
Ha44 Gel 0.74% w/wDr. Reddy's LaboratoriesPhase 2
32
Abametapir Lotion 0.74% w/w + Vehicle LotionDr. Reddy's LaboratoriesPhase 3
37
Abametapir Lotion 0.74% w/wDr. Reddy's LaboratoriesPhase 1
26
DFN-11 InjectionDr. Reddy's LaboratoriesPhase 2
24
Abametapir Lotion 0.74% w/w + Sodium Lauryl Sulfate + Saline 0.9% + PlaceboDr. Reddy's LaboratoriesPhase 1
26
Abametapir Lotion 0.74% w/w + Vehicle LotionDr. Reddy's LaboratoriesPhase 2
32
Ha44 GelDr. Reddy's LaboratoriesPhase 2
32
AFM24 + SNK01AffimedPhase 1/2
14
Cemiplimab + CetuximabEli LillyPhase 2
42
BB-401Benitec BiopharmaPhase 2
25
Placebo + LY2300559Eli LillyPhase 2
27
Gemcitabine + ACR-368Acrivon TherapeuticsPhase 2
32
Ketorolac + Prochlorperazine + DiphenhydramineAssertio HoldingsPhase 2
17
Ramucirumab + PembrolizumabEli LillyPhase 2
39
Ozuriftamab Vedotin + Pembrolizumab + Evalstotug (BA3071) + CetuximabBioAtlaPhase 2
25
Patritumab + Cetuximab + Cisplatin + Carboplatin + PlaceboDaiichi SankyoPhase 2
27
Patritumab + Cetuximab + Cisplatin + CarboplatinDaiichi SankyoPhase 1
29
cevimeline hydrochlorideDaiichi SankyoPhase 3
40